Welcome news about levodopa, but uncertainty remains
1998; Wiley; Volume: 43; Issue: 5 Linguagem: Inglês
10.1002/ana.410430502
ISSN1531-8249
Autores Tópico(s)Genetic Neurodegenerative Diseases
ResumoAnnals of NeurologyVolume 43, Issue 5 p. 551-554 Editorial Welcome news about levodopa, but uncertainty remains Stanley Fahn MD, Stanley Fahn MD Department of Neurology, Columbia University, New York, NYSearch for more papers by this author Stanley Fahn MD, Stanley Fahn MD Department of Neurology, Columbia University, New York, NYSearch for more papers by this author First published: 08 October 2004 https://doi.org/10.1002/ana.410430502Citations: 19AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Cotzias GC, van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374– 379 2 Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969; 280: 337– 345 3 Sacks OW. Awakenings. Garden City, NY, Doubleday & Co, 1974 4 Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966; 18: 925– 964 5 Fahn S. The history of parkinsonism. Mov Disord 1989; 4 (Suppl 1): S2– S10 6 Muenter MD, Tyce GM. L-Dopa therapy of Parkinson's disease:plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971; 46: 231– 239 7 Fahn S. Adverse effects of levodopa. In CW Olanow, AN Lieberman, eds. The scientific basis for the treatment of parkinson's disease. Carnforth, UK, Parthenon, 1992: 89– 112 8 Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973; 20: 415– 455 9 Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psych Res 1979; 1: 249– 254 10 Burns RS, Chiueh CC, Markey SP, et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983; 80: 4546– 4550 11 Langston JW, Forno LS, Rebert CS, Irwin I. 1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine causes selective damage to the zona compacta of the substantia nigra in the squirrel monkey. Brain Res 1984; 292: 390– 394 12 Calne DB, Stern GM, Laurence DR, et al. L-Dopa in postencephalitic parkinsonism. Lancet 1969; 1: 744– 746 13 Sacks OW, Kohl M, Schwartz W, Messeloff C. Side-effects of L-dopa in postencephalitic parkinsonism. Lancet 1970; 1: 1006 (Letter) 14 Duvoisin RC, Lobo-Antunes J, Yahr MD. Responses of patients with postencephalitic parkinsonism to levodopa. J Neurol Neurosurg Psych 1972; 35: 487– 495 15 Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979– 980 16 Langston JW, Ballard PA. Parkinsonism induced by 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine: implications for treatment and the pathophysiology of Parkinson's disease. Can J Neurosci 1984; 11: 160– 165 17 Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985; 35: 949– 956 18 Rodriguez M, Lera G, Vaamonde J, et al. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psych 1994: 57: 562– 566 19 Metman LV, Locatelli ER, Bravi D, et al. Apomorphine responses in parkinson's disease and the pathogenesis of motor complications. Neurology 1997: 48: 369– 372 20 Yahr MD. Evaluation of long-term therapy in Parkinson's disease: Mortality and therapeutic efficacy. In W Birkamayer, O Hornykiewicz, eds. Advances in parkinsonism. Basel, Editiones Roche, 1976: 444– 455 21 Markham CH, Diamond SG. Long-term follow up of early dopa treatment in Parkinson's disease. Ann Neurol 1986; 19: 365– 372 22 Jenner P, Dexter DT, Sian J, et al. Oxidative stress as a cause of nigral cell death in parkinson's disease and incidental Lewy body disease. Ann Neurol 1992; 32 (Suppl): S82– S87 23 Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804– 812 24 Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 1988; 86: 1398– 1400 25 Spencer JPE, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-DOPA and its metabolites implications for neurodegenerative disease. FEBS Lett 1994; 353: 246– 250 26 Spencer JPE, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathoine by L-DOPA and dopamine: Relevance to Parkinson's disease. Neuroreport 1995; 6: 1480– 1484 27 Jenner P. The rationale for the use of dopamine agonists iN Parkinson's disease. Neurology 1995; 45 (Suppl 3): 6– 12 28 Fahn, S. Is levodopa toxic? Neurology 1996; 47 (Suppl): S184– S195 29 Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43: 561– 575 30 Fahn S. Levodopa-induced neurotoxicity: does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 1997; 8: 376– 393 31 Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats preoviously exposed to the neurotoxin 6-hydroxy-dopamine. Mov Disord 1993; 8: 129– 133 32 Fukuda T, Watabe K, Tanaka J. Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res 1996; 728: 274– 276 33 Mena MA, Casarejos MJ, Carazo A, et al. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. Neuroreport 1996; 7: 441– 445 34 Mena MA, Casarejos MJ, Carazo A, et al. Glia protect fetal midbrain dopamine neurons in culture form L-DOPA toxicity through multiple mechanisms. J Neural Transm 1997; 104: 317– 328 35 Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron cortical astrocyte cocultures. J Neurochem 1997; 69: 1398– 1408 36 Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987; 22: 535– 540 37 Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990; 27: 18– 23 38 Sage JI, McHale DM, Sonsalla P, et al. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease. Neurology 1989; 39: 888– 891 39 Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa carbidopa in Parkinson's disease patients with on-off fluctuations. Neurology 1993; 43: 1698– 1703 40 Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisatation of the therapeutic effect in severE Parkinson's disease. Eur J Clin Pharmacol 1993; 45: 117– 122 41 Obeso JA, Vaamonde J, Grandas F, et al. Overcoming pharmacokinetic problems in the treatment of Parkinson's disease. Mov Disord 1989; 4 (Suppl 1): S70– S85 42 Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994; 44 (Suppl): S15– S18 Citing Literature Volume43, Issue5May 1998Pages 551-554 ReferencesRelatedInformation
Referência(s)